


Reasons to invest

LO Funds – Global HealthTech

Why invest?

p.4



Global Equities



Publication issued by Lombard Odier Asset Management (Europe) Limited (“LOIM”)

Lombard Odier Funds (“LO Funds”) is a variable capital investment company (SICAV) incorporated in Luxembourg as an Undertaking for Collective Investments in Transferable Securities (UCITS) subject to Luxembourg laws. LO Global HealthTech is a Sub-Fund of LO Funds.

This marketing document is for retail investors located in the countries listed in the Key Facts section. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000. It is not appropriate for retail investors in Singapore or any US person / UCITS have no guaranteed return and past performance does not guarantee the future ones. Please read the important information at the end of this document.

p.2-7

· Product overview	2
· Why invest?	4
· Investment philosophy and process	5
· The investment team	5
· Sub-Fund key facts	6
· Understanding risks & glossary	7

Providing better care
at lower cost.

Product overview

ASSET CLASS

Global equities.

APPROACH

High Conviction.

Digitalisation is set to transform global healthcare.

*Companies looking to capitalise on the key themes of **prevention, efficiency and connected care** will be at the forefront of this global health care revolution.*

We believe the companies embracing this digitalization trend will offer better potential health outcomes for patients with compelling long-term growth opportunities for investors.

¹ Source: LOIM. Past performance is not a guarantee of future results. There can be no assurance that the Sub-Fund's investment objective will be achieved or that there will be a return on capital or that a substantial loss will not be incurred.

Quality companies benefitting from better and more affordable healthcare through digitalisation




Connected Care

Connecting to your physician via telehealth will become the norm just as wearing connected devices that constantly measure your vital signs.



Prevention

Healthcare will refocus on prevention with the use of better and earlier diagnostics, personal medicine and lifestyle changes.



Efficiency

By embracing automation, artificial intelligence and outsourcing the healthcare system will become simpler, faster and more affordable.

Source: LOIM. For illustrative purposes only.

This marketing document is for retail investors located in the countries listed on Section – Key Facts. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

Why invest?

The healthcare system today is expensive, hospital-centered and inefficient, weighed down by an ageing population. Healthcare is the least digitalised sector, now ripe for a digital revolution that may lower costs and increase access for all.

“A digitalised healthcare system aims to lower costs and increase availability of basic healthcare.”

Long-term megatrend investing

Our experienced team are investing in breakthrough technologies that increase life expectancy, while also advancing the UN SDG 3 goal. A high conviction, disciplined bottom-up selection of 40-60 companies we believe will stand to benefit greatly from technology efficiencies.

A digitalised and more efficient healthcare system

COVID-19 has promoted the quantum leap needed for healthcare into the 21st digital century. While support from governments & regulators will be critical in this transition, connectivity of healthcare data is a prerequisite in this transformation enabled by AI, machine learning and cloud computing. This more digitized and efficient system will result in reduced healthcare spending at an individual level and globally, more of the world’s population being able to access healthcare, leading in turn to better health outcomes for patients. Companies that aim to make healthcare cheaper and more efficient should benefit from a larger market share.


Healthcare transformation – prevention, efficiency and connected care

Prevention



Healthy behaviours account for 50% of what make us healthy, yet this is only 4% of our health care spend. Companies encouraging prevention rather than cure through lifestyle changes could be at a competitive advantage. These opportunities can include DNA-based treatments and cheap early detection diagnostics such as liquid biopsies.

Efficiency



Healthcare automation brings efficiency. Artificial intelligence driven radiology, robot surgery, automated pharmacies, real time case prioritization and triage, and personalized medications are just some of the many cost-reducing technologies being developed by leading healthcare companies.

Connected care




Digital wearable devices are now putting the patient in charge, with Telehealth now set to become the efficient digital health platform. Approved by more and more governments, those companies tapping into unused capacity across primary care, mental care as well as wellness and prevention could prove compelling for investors.

¹ Source: For illustrative purposes only. There can be no assurance that the investment objective will be achieved or that there will be a return on capital or that a substantial loss will not be incurred. / UN Sustainable Development Goal 3 (or ‘UN SDG3’), aims «To ensure healthy lives and promote well-being for all at all ages.» and is one of the United Nations’ 17 Sustainable Development Goals.

This marketing document is for retail investors located in the countries listed on Section – Key Facts. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

Investment philosophy and process

A well-defined investment process



The investment team



Henk Grootveld
Co portfolio Manager
25 years investment experience



Jerome Berton
Co portfolio Manager
20 years investment experience



Didier Rabattu
Head of Equities,
Limited Partner
23 years' experience



Pascale Menges
Head of Research &
Investment Process
23 years experience

Source: LOIM as at 31 July 2021. The investment management team is subject to change without notice. ¹ The number of years denotes years of investment industry experience.

“HealthTech today is where e-commerce was in the ‘90s”

For illustrative purposes only. Holdings/allocation are subject to change. Past performance and forecasts are not a reliable indicator of future returns of the Sub-Fund. For more information on the LOIM ESG process please refer to the following link: <https://am.lombardodier.com/home/the-sustainability-revolution-wi.html>. / ¹ There can be no assurance that the Sub-Fund's investment objective will be achieved or that there will be a return on capital or that a substantial loss will not be incurred.

This marketing document is for retail investors located in the countries listed on Section – Key Facts. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

Key facts about LO Funds – Global HealthTech

Legal structure	SICAV – UCITS (Luxembourg) ¹
Investment objectives	The Sub-Fund is actively managed. The MSCI ACWI TR ND index is used for performance comparison as well as internal risk monitoring purposes, without implying any particular constraints to the Sub-Fund's investments. Securities targeted by the Sub-Fund can be similar to those of the index to an extent that varies overtime but their weighting is expected to materially differ. The performance of the Sub-Fund may deviate materially from that of the above-mentioned index. The Sub-Fund invests primarily in equity and equity related securities of companies worldwide (including Emerging Markets) that are active in the research, development, production, promotion and/or distribution of digital healthcare products, services and/or technologies. The Sub-Fund may invest across all economic sectors (including, but not limited to, companies that support the supply chain of, and provide services for, these companies). The Sub-Fund seeks to invest in high quality companies with sustainable financial models, business practices and business models showing resilience and the ability to evolve and benefit from long term structural trends using LOIM proprietary ESG and Sustainability Profiling tools and methodologies. As part of its Emerging Market exposure, the Sub-Fund may invest up to 20% of its net assets in shares issued by mainland China-incorporated companies (including China A-Shares). The Investment Manager is authorized to use financial derivative instruments for hedging purposes or for EPM but not as part of the investment strategy.
Investor profile	This Sub-Fund may not be appropriate for investors who plan to withdraw their money within 5 years.
Sub-Fund launch	20 September 2021
Custodian bank/administration	CACEIS Bank, Luxembourg Branch
Liquidity	Daily
Subscription/redemption details	15:00 CET; Payment date: T-1 Please note the subfund seeding period runs from 6 September 2021 to 29 October 2021 at 3pm CET.
Registered countries/ Investor type	Registered for distribution to retail investors in: Austria (AT), Finland (FI), France (FR), Germany (DE), Italy (IT), Liechtenstein (LI), Luxembourg (LU), Netherlands (NL), Norway (NO), Spain (ES), Sweden (SE), United Kingdom (GB). Switzerland (CH): Registered for distribution to Swiss retail investors with the FINMA. Belgium (BE): Not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000. US: Not appropriate for U.S. persons.
Reference currency	USD
Minimum investment	EUR 3,000 (Class P)
Management fee	0.375%
Distribution fee	0.75%
Conversion fee	Up to 0.50% (of the total amount switched)
Taxation in the EU	Tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Please consult your tax advisor for more details.


Share Class	ISIN	SRRI	Exit Charge	Ongoing Charge (est.d) ²	Performance Fee	Countries of registration ³
LO Funds – Global HealthTech, Seed, (USD), P A	LU2366399595	6	0%	1.48%	None	AT, BE, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, SE
LO Funds – Global HealthTech, Seed, (USD), P D	LU2366403025	6	0%	1.48%	None	AT, BE, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, SE
LO Funds – Global HealthTech, Syst. NAV Hdg, Seed, (EUR), P A	LU2366389364	6	0%	1.48%	None	AT, BE, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, SE
LO Funds – Global HealthTech, Syst. NAV Hdg, Seed, (EUR), P D	LU2366389281	6	0%	1.48%	None	AT, BE, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, SE
LO Funds – Global HealthTech, Syst. NAV Hdg, Seed, (CHF), P A	LU2366400195	6	0%	1.48%	None	AT, BE, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, SE
LO Funds – Global HealthTech, Syst. NAV Hdg, Seed, (CHF), P D	LU2366399835	6	0%	1.48%	None	AT, BE, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, SE
LO Funds – Global HealthTech, Syst. NAV Hdg, Seed, (GBP), P A	LU2366392319	6	0%	1.48%	None	AT, BE, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, SE
LO Funds – Global HealthTech, Syst. NAV Hdg, Seed, (GBP), P D	LU2366392236	6	0%	1.48%	None	AT, BE, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, SE

The above share classes are for illustrative purposes only. Other share classes may be available in your country. The prospectus, the Key Investor Information Documents (KIIDs), the articles of incorporation as well as the semi-annual and annual reports are available on www.loim.com and can be requested free of charge at the registered office of the Sub-Fund.

¹ Lombard Odier Funds (“LO Funds”) is a variable capital investment company (SICAV) incorporated in Luxembourg as an Undertaking for Collective Investments in Transferable Securities (UCITS) subject to Luxembourg laws. LO Funds – Global HealthTech is a Sub-Fund of LO Funds. / ² The ongoing charges figure is estimated and is currently based on the Total Expense Ratio (“TER”). This figure may vary periodically. / ³ The Sub-Fund is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

This marketing document is for retail investors located in the countries listed on Section – Key Facts. It is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000.

Understanding the risk & glossary



This indicator (SRRI) represents the annualised historical volatility of the Sub-Fund over a 5-year period. Where there are less than 5 years' worth of data, missing returns are simulated using an appropriate benchmark. The SRRI may change over time and should not be used as an indicator of future risk or returns. Even the lowest risk classification does not imply that the Sub-Fund is risk-free or that capital is necessarily guaranteed or protected.

The SRRI related to the share classes under marketing may vary from 5 to 7. The value of the share classes exposed to high volatility may be subject to high variations both upward and downward that may create important short-term latent losses.

The following risks may be materially relevant but may not always be adequately captured by the synthetic risk indicator and may cause additional loss:

Concentration risk:

To the extent that the fund's investments are concentrated in a particular country, market, industry, sector or asset class, the fund may be susceptible to loss due to adverse occurrences affecting that country, market, industry, sector or asset class.

Emerging market risk:

Significant investment in emerging markets may expose to difficulties when buying and selling investments. Emerging markets are also more likely to experience political uncertainty and investments held in these countries may not have the same protection as those held in more developed countries.

Active management risk:

Active management relies on anticipating various market developments and/or security selection. There is a risk at any given time that the fund may not be invested in the highest-performing markets or securities. The fund's net asset value may also decline

Before taking any investment decision, please read the latest version of the Prospectus, the articles of incorporation, the Key Investor Information Documents (KIIDs) and the latest annual report and semi-annual report. Please pay particular attention to Appendix B "Risk Factors Annex" of the Prospectus.

Please also pay particular attention to inherent risks of the Sub-Fund such as:

- Risks related to Equities;
- Risks related to Small and Medium Sized Capitalisations;
- Risks related to Currencies;
- Risks related to Regional and Sectorial Concentration.

Before taking any investment decision, please read the latest version of the prospectus, the articles of incorporation, the Key Investor Information Documents (KIIDs) and the latest annual report and semi-annual report. Please pay attention to the Appendix B "Risk Factors Annex" of the prospectus.

Glossary

For a glossary of terms, please see <https://am.lombardodier.com/home/glossary.html>

Contact

To find out more about LO Funds – Global HealthTech, email loim-funds@lombardodier.com

or visit www.loim.com   @loimnews

IMPORTANT INFORMATION

Lombard Odier Funds (hereinafter the “Fund”) is a Luxembourg investment company with variable capital (SICAV). The Fund is authorised and regulated by the Luxembourg Supervisory Authority of the Financial Sector (CSSF) as an Undertaking for Collective Investments in Transferable Securities UCITS under Part I of the Luxembourg law of the 17 December 2010 implementing the European directive 2009/65/EC, as amended (“UCITS Directive”). This marketing document relates to “LO Funds – Global HealthTech,” a Sub-Fund of Lombard Odier Funds (hereinafter the “Sub-Fund”). The Management Company of the Fund is Lombard Odier Funds (Europe) S.A. (hereinafter the “Management Company”), a Luxembourg based public limited company (SA), having its registered office at 291, route d’Arlon, 1150 Luxembourg, Grand Duchy of Luxembourg, authorised and regulated by the CSSF as a Management Company within the meaning of EU Directive 2009/65/EC, as amended; and within the meaning of the EU Directive 2011/61/EU on Alternative Investment Fund Managers (AIFMD). The purpose of the Management Company is the creation, promotion, administration, management and the marketing of Luxembourg and foreign UCITS, alternative investment funds (“AIFs”) and other regulated funds, collective investment vehicles or other investment vehicles, as well as the offering of portfolio management and investment advisory services. The Management Company of the Fund may decide to terminate the arrangements made for the marketing of the Sub-Fund.

A summary of investor rights is available on <https://am.lombardodier.com/home/asset-management-regulatory-disc.html>.

This marketing communication was prepared by Lombard Odier Asset Management (Europe) Limited. The prospectus, the articles of incorporation, the Key Investor Information Documents, the subscription form and the most recent annual and semi-annual reports are the only official offering documents of the Sub-Fund’s shares (the “Offering Documents”). The Offering Documents are available in English, French, German and Italian at www.loim.com and can be requested free of charge at the registered office of the Sub-Fund in Luxembourg: 291 route d’Arlon, 1150 Luxembourg, Grand Duchy of Luxembourg. The information contained in this marketing communication does not take into account any individual’s specific circumstances, objectives or needs and does not constitute research or that any investment strategy is suitable or appropriate to individual circumstances or that any investment or strategy constitutes a personal investment advice to any investor. This marketing communication is not intended to substitute any professional advice on investment in financial products. Before making an investment in the Sub-Fund, an investor should read the entire Offering Documents, and in particular the risk factors, costs and conditions pertaining to an investment in the Sub-Fund. We would like to draw the investor’s attention toward the long-term nature of delivering returns across the economic cycle and the use of financial derivative instruments as part of the investment strategy may result in a higher level of leverage and increase the overall risk exposure of the Sub-Fund and the volatility of its Net Asset Value. Investors should take care to assess the suitability of such investment to his/her particular risk profile and circumstances and, where necessary, obtain independent professional advice in respect of risks, as well as any legal, regulatory, credit, tax, and accounting consequences. There can be no assurance that the Sub-Fund’s investment objective will be achieved or that there will be a return on capital. Past performance is not a reliable indicator of future results. Where the Sub-Fund is denominated in a currency other than an investor’s base currency, changes in the rate of exchange may have an adverse effect on price and income. Please take note of the risk factors. Any benchmarks/indices cited herein are provided for information purposes only. No benchmark/index is directly comparable to the investment objectives, strategy or universe of a Sub-Fund. The performance of a benchmark shall not be indicative of past or future performance of any Sub-Fund. It should not be assumed that the relevant Sub-Fund will invest in any specific securities that comprise any index, nor should it be understood to mean that there is a correlation between such Sub-Fund’s returns and any index returns. Target performance/risk represents a portfolio construction goal. It does not represent past performance/risk and may not be representative of actual future performance/risk.

MSCI information may only be used for internal purposes, may not be reproduced or disseminated in any form whatsoever and may not be used as the basis or constituent element of any financial instruments, products or indices. MSCI information should not be construed as investment advice or recommendations to you to make (or refrain from making) any investment decision and cannot, as such, be considered reliable. Historical data and analyses should not be considered as any indication or guarantee in any analysis, forecast or prediction of future performance. MSCI information is provided “as is” and the user of this information assumes full responsibility for the use that is made of this information. MSCI, each of its affiliates and others involved in or concerned with the compilation, calculation or creation of MSCI information (collectively the “MSCI Parties”) expressly disclaim all warranties (including, without limitation, all warranties of originality, accuracy, completeness, timeliness, non-infringement, market value and fitness for a specific purpose) with respect to such information. Without limiting the foregoing, in no event shall the MSCI Parties be liable for any direct, indirect, specific, incidental, punitive, consequential (including, without limitation, lost profits) or other damages. (www.msci.com).

The information and analysis contained herein are based on sources considered to be reliable. Lombard Odier makes its best efforts to ensure the timeliness, accuracy,

and completeness of the information contained in this marketing communication. Nevertheless, all information and opinions as well as the prices, market valuations and calculations indicated herein may change without notice. Source of the figures: Unless otherwise stated, figures are prepared by Lombard Odier Asset Management (Europe) Limited. The tax treatment depends on the individual circumstances of each client and may be subject to change in the future. Lombard Odier does not provide tax advice and it is up to each investor to consult with its own tax advisors.

NOTICE TO RESIDENTS IN THE FOLLOWING COUNTRIES: Austria – Paying agent: Erste Bank der österreichischen Sparkassen AG. Belgium – Financial services provider: CACEIS Belgium S.A. The Sub-Fund is not appropriate for Belgian retail investors unless the investment subscription is more than EUR 250,000. Please contact your tax advisor to identify the Belgian tax “TOB” (“Taxe sur les Opérations Boursières”) on your transactions, as well as the impacts of the withholding tax (“Précomptes mobiliers”). Lombard Odier has an internal Complaints Management Service. You can lodge a claim via your Relationship Manager or directly to Lombard Odier (Europe) S.A. Luxembourg, Belgium Branch, Claim Management Service, Avenue Louise 81, Box 12, 1050 Brussels, Fax: (+32) 2 543 08. Alternatively you can address your complaint free of charge to the national complaint service in Belgium, OMBUDSMAN: North Gate II, Boulevard du Roi Albert II, n°8 Boite 2 2, 1000 Brussels, Tel: (+32) 2 545 77 70, Fax: (+32) 2 545 77 79, Email: Ombudsman@Ombusfin.be. France – Centralising agent: CACEIS Bank. Germany – German Information and Paying agent: DekaBank Deutsche Girozentrale. Italy – Paying agents: Società Generale Securities Services S.p.A., State Street Bank International GmbH – Succursale Italia, Banca Sella Holding S.p.A., Allfunds Bank S.A.U., Milan Branch, BNP Paribas Securities Services, CACEIS Bank, Italy Branch. Liechtenstein – Paying agent: LGT Bank AG. Luxembourg – Depository, central administration agent, registrar, transfer agent, paying agent and listing agent: CACEIS Bank, Luxembourg Branch. Netherlands – Paying agent: Lombard Odier Funds (Europe) S.A. – Dutch Branch. Spain – Paying agent: Allfunds Bank S.A.U. – CNMV Number: 498. Sweden – Paying agent: Skandinaviska Enskilda Banken AB (publ). Switzerland – The Sub-Fund is registered with the Swiss Federal Financial Market Supervisory Authority (FINMA). The Offering Documents together with the other Shareholders’ information are available free of charge at the Swiss Representative: Lombard Odier Asset Management (Switzerland) S.A., 6, avenue des Morgines, 1213 Petit-Lancy, Switzerland. Swiss Paying Agent: Banque Lombard Odier & Co Ltd, 11, rue de la Corratierie 1204 Genève, Switzerland. Publications about the Sub-Fund: www.fundinfo.com. The issue and redemption prices and / or the net asset value (with the mention “excluding commissions”) of the Share classes distributed in Switzerland: www.swissfunddata.ch and www.fundinfo.com. Bank Lombard Odier & Co Ltd is a bank and securities dealer authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). United Kingdom – This document is a financial promotion and has been approved for the purposes of Section 21 of the Financial Services and Markets Act 2000, by Lombard Odier Asset Management (Europe) Limited. It is approved for distribution by Lombard Odier (Europe) S.A., London Branch for Retail Clients in the United Kingdom. The Sub-Fund is a Recognised scheme in the United Kingdom under the Financial Services and Markets Act 2000. UK regulation for the protection of retail clients in the UK and the compensation available under the UK Financial Services Compensation scheme does not apply in respect of any investment or services provided by an overseas person. UK facilities agent: Lombard Odier Asset Management (Europe) Limited. Lombard Odier (Europe) S.A. UK Branch is a credit institution regulated in the UK by the Prudential Regulation Authority (PRA) and subject to limited regulation by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA). Details of the extent of our authorisation and regulation by the PRA and regulation by the FCA are available from us on request. European Union Members: This marketing communication has been approved for issue by Lombard Odier (Europe) S.A. The entity is a credit institution authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) in Luxembourg. Lombard Odier (Europe) S.A. branches are operating in the following territories: Belgium: Supervisory Authority: Autorité des services et marchés financiers (FSMA), Representative: CACEIS Belgium S.A., Avenue du Port 86C, b320, 1000 Brussels; France: Lombard Odier (Europe) S.A. Succursale en France, a credit institution under limited supervision in France by the Autorité de contrôle prudentiel et de résolution (ACPR) and by the Autorité des marchés financiers (AMF) in respect of its investment services activities; Italy: Lombard Odier (Europe) S.A. Succursale in Italia, enrolled in the Milan Companies Register No. 09514880963, R.E.A. No. MI – 2095300 Regulated in Italy by the Commissione Nazionale per la Società e la Borsa (CONSOB) and la Banca d’Italia; Spain: Lombard Odier (Europe) S.A. Sucursal en España, Lombard Odier Gestión (España) S.G.I.I.C., S.A.U., credit institutions under limited supervision in Spain by the Banco de España and the Comisión Nacional del Mercado de Valores (CNMV). United States: The Fund and Sub-Fund is not registered under the “Securities Act of 1933” as amended and therefore, cannot be sold, offered or distributed to any “U.S. Person” as defined under “Regulation S”. Neither this document nor any copy thereof may be sent, taken into, or distributed in the United States or given to any US person. This marketing communication may not be reproduced (in whole or in part), transmitted, modified, or used for any public or commercial purpose without the prior written permission of Lombard Odier.

© 2022 Lombard Odier Investment Managers – all rights reserved.